VORICONAZOLE

By Gary M. White, MD


Voriconazole is an oral antifungal agent that has been reported to have various dermatologic effects, the most notable being the predisposition to melanoma and squamous cell carcinoma formation. These effects include:

Voriconazole is FDA approved for children older than 2 years of age. Approximately 20% of children on voriconazole develop photo toxicity [JAAD 2015;72;314]. White race and high cumulative dose are risk factors. In one study from UCSF, voriconazole increased the risk of SCC by 73% in lung transplant patients. [Dermatology News, May 2015 p. 10].

Treatment

Patients of any age should be counseled on photo protection and receive routine surveillance for skin cancer.

RegionalDerm

Homepage | FAQs | Use of Images | Contact Dr. White


It is not the intention of RegionalDerm.com to provide specific medical advice, diagnosis or treatment. RegionalDerm.com only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on RegionalDerm.com is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on RegionalDerm.com should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.